Business Segments · R&D
Business Segments — R&D
Veradermics Business Segments — R&D increased by 85.3% to $17.19M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toR&D
How to read this metric
An increase typically signals aggressive investment in the product pipeline, while a decrease may indicate a shift toward commercialization or cost-cutting.
Detailed definition
This metric represents the total expenditures allocated to the research and development segment, specifically focusing o...
Peer comparison
Commonly reported as R&D expense by all biopharmaceutical peers, often benchmarked as a percentage of total operating expenses.
Metric ID:
mane_segment_reportable_segment_research_and_developmentHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $9.28M | $17.19M |
| QoQ Change | — | +85.3% |
| YoY Change | — | +85.3% |
Range$9.28M – $17.19M
Avg YoY Growth+85.3%
Median YoY Growth+85.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Veradermics 's business segments — r&d?
- Veradermics (MANE) reported business segments — r&d of $17.19M in Q1 2026.
- What does business segments — r&d mean?
- The total costs dedicated to developing new products and conducting clinical research.